Hartford Financial Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.53K | Sell |
39
-24
| -38% | -$2.01K | ﹤0.01% | 314 |
|
|
2026
Q1 | $5.05K | Hold |
63
| – | – | ﹤0.01% | 293 |
|
|
2025
Q4 | $5.37K | Hold |
63
| – | – | ﹤0.01% | 291 |
|
|
2025
Q3 | $4.9K | Buy |
63
+33
| +110% | +$2.58K | ﹤0.01% | 292 |
|
|
2025
Q2 | $2.35K | Hold |
30
| – | – | ﹤0.01% | 318 |
|
|
2025
Q1 | $2.17K | Hold |
30
| – | – | ﹤0.01% | 334 |
|
|
2024
Q4 | $2.22K | Hold |
30
| – | – | ﹤0.01% | 355 |
|
|
2024
Q3 | $1.98K | Hold |
30
| – | – | ﹤0.01% | 364 |
|
|
2024
Q2 | $2.77K | Hold |
30
| – | – | ﹤0.01% | 347 |
|
|
2024
Q1 | $2.87K | Hold |
30
| – | – | ﹤0.01% | 353 |
|
|
2023
Q4 | $2.29K | Hold |
30
| – | – | ﹤0.01% | 367 |
|
|
2023
Q3 | $2.08K | Hold |
30
| – | – | ﹤0.01% | 368 |
|
|
2023
Q2 | $2.83K | Hold |
30
| – | – | ﹤0.01% | 336 |
|
|
2023
Q1 | $2.48K | Hold |
30
| – | – | ﹤0.01% | 339 |
|
|
2022
Q4 | $2.24K | Sell |
30
-20
| -40% | -$1.54K | ﹤0.01% | 343 |
|
|
2022
Q3 | $4K | Hold |
50
| – | – | ﹤0.01% | 320 |
|
|
2022
Q2 | $5K | Hold |
50
| – | – | ﹤0.01% | 317 |
|
|
2022
Q1 | $6K | Buy |
+50
| New | +$5.61K | ﹤0.01% | 317 |
|
|
2021
Q4 | – | Sell |
-20
| Closed | -$2K | – | 376 |
|
|
2021
Q3 | $2K | Buy |
+20
| New | +$2.28K | ﹤0.01% | 370 |
|
|
2018
Q1 | – | Sell |
-240
| Closed | -$9K | – | 353 |
|
|
2017
Q4 | $9K | Hold |
240
| – | – | ﹤0.01% | 275 |
|
|
2017
Q3 | $8K | Hold |
240
| – | – | ﹤0.01% | 310 |
|
|
2017
Q2 | $9K | Hold |
240
| – | – | ﹤0.01% | 290 |
|
|
2017
Q1 | $7K | Hold |
240
| – | – | ﹤0.01% | 282 |
|
|
2016
Q4 | $7K | Hold |
240
| – | – | ﹤0.01% | 258 |
|
|
2016
Q3 | $9K | Hold |
240
| – | – | 0.01% | 243 |
|
|
2016
Q2 | $7K | Hold |
240
| – | – | ﹤0.01% | 233 |
|
|
2016
Q1 | $7K | Hold |
240
| – | – | ﹤0.01% | 226 |
|
|
2015
Q4 | $6K | Buy |
+240
| New | +$6.23K | ﹤0.01% | 232 |
|
|
2015
Q3 | – | Sell |
-240
| Closed | -$5K | – | 263 |
|
|
2015
Q2 | $5K | Buy |
+240
| New | +$5.42K | ﹤0.01% | 240 |
|
|
2015
Q1 | – | Sell |
-240
| Closed | -$5K | – | 145 |
|
|
2014
Q4 | $5K | Hold |
240
| – | – | ﹤0.01% | 221 |
|
|
2014
Q3 | $4K | Hold |
240
| – | – | ﹤0.01% | 255 |
|
|
2014
Q2 | $3K | Hold |
240
| – | – | ﹤0.01% | 267 |
|
|
2014
Q1 | $2K | Hold |
240
| – | – | ﹤0.01% | 250 |
|
|
2013
Q4 | $2K | Hold |
240
| – | – | ﹤0.01% | 238 |
|
|
2013
Q3 | $2K | Hold |
240
| – | – | ﹤0.01% | 253 |
|
|
2013
Q2 | $3K | Buy |
+240
| New | +$2.84K | ﹤0.01% | 249 |
|
Other funds holding EW
Hartford Financial Management's EW Position: Q2 2026 in Review
Hartford Financial Management reduced its Edwards Lifesciences (EW) stake by 38% in Q2 2026, selling an estimated $2.01K and leaving 39 shares worth $3.53K. The position accounts for ﹤0.01% of the portfolio, ranked #314.
Hartford Financial Management first reported a position in EW in Q2 2013 and has held it in 36 quarters since. The position peaked at $9K in Q4 2017. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Hartford Financial Management held 39 shares of Edwards Lifesciences worth $3.53K as of Q2 2026.
- Hartford Financial Management sold 24 Edwards Lifesciences shares in Q2 2026, an estimated $2.01K.
- Edwards Lifesciences made up ﹤0.01% of Hartford Financial Management's portfolio in Q2 2026, its #314 holding.
- Hartford Financial Management first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 36 quarters since.
- Hartford Financial Management's Edwards Lifesciences position peaked at $9K in Q4 2017.
- 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Hartford Financial Management's 13F filing for Q2 2026, filed 24 Jul 2026.